Miriplatin(Synonyms: SM-11355)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Miriplatin (Synonyms: SM-11355) 纯度: ≥98.0%

Miriplatin (SM-11355) 为有效的化疗剂,是烷化剂 (alkylator) 的一种。

Miriplatin(Synonyms: SM-11355)

Miriplatin Chemical Structure

CAS No. : 141977-79-9

规格 价格 是否有货 数量
5 mg ¥500 In-stock
10 mg ¥700 In-stock
50 mg ¥1400 In-stock
100 mg ¥2200 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Miriplatin 相关产品

相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • Bioactive Compound Library Plus

生物活性

Miriplatin (SM-11355) is a chemotherapy agent which belongs to the class of alkylating agents.

体外研究
(In Vitro)

Miriplatin (SM-11355) suspended in LPD (miriplatin/LPD, 100 μg/mL) inhibits the growth of AH109A cells, forms platinum-DNA adducts, and induces apoptosis[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Miriplatin (SM-11355) (0.02-0.4 mg/20 μL) in lipiodol reduces tumor growth rates in a dose dependent manner in rats bearing AH109A tumor cells[1]. Miriplatin/LPD (400 μg/head) significantly reduces the growth of tumor in rats bearing AH109A cells[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

764.00

Formula

C34H68N2O4Pt

CAS 号

141977-79-9

中文名称

米铂

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

Acetone : < 1 mg/mL (ultrasonic) (insoluble; DMSO can inactivate Miriplatin’s activity)

DMF : < 1 mg/mL (insoluble; DMSO can inactivate Miriplatin’s activity)

H2O : < 0.1 mg/mL (insoluble; DMSO can inactivate Miriplatin’s activity)

*Miriplatin is usually formulated as a suspension.

参考文献
  • [1]. Kishimoto S, et al. Antitumor effects of a novel lipophilic platinum complex (SM-11355) against a slowly-growing rat hepatic tumor after intra-hepatic arterial administration. Biol Pharm Bull. 2000 Mar;23(3):344-8.

    [2]. Hanada M, et al. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol. 2009 Aug;64(3):473-83.

Cell Assay
[2]

Aliquots of AH109A cells are plated into 24-well microplates. Following cell adherence (1 day), Lipiodol (LPD) alone and agents (Miriplatin, etc.) suspended in LPD are added to Falcon cell culture inserts, equipped with a 0.4-μm pore membrane on their bottom. After 7 days of incubation at 37°C in 5% CO2, the numbers of viable cells are examined using AlamarBlue. The IC50 value is defined as the concentration inhibiting cell growth by 50% compared with treatment with LPD alone. To examine platinum concentrations in the medium, agents suspended in LPD are added to Falcon cell culture inserts in wells containing the culture medium alone. The platinum concentrations are quantitatively analyzed by FAAS. Alternatively, aliquots of AH109A cells are plated into 96-well microplates. Following cell adherence (1 day), agents in aqueous solution are added. After 3 days of incubation at 37°C in 5% CO2, the numbers of viable cells are examined using AlamarBlue[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[2]

Rats[2]
Rats bearing a tumor approximately 100-250 mm3 in area are randomly allocated into different treatment groups and a control group, each of which consists of seven rats. Tumor diameters are measured with calipers, and estimated tumor area is calculated by the formula: (smaller diameter) × (larger diameter). All agents (Miriplatin, etc.) suspended in Lipiodol (LPD) and LPD alone are injected into the hepatic artery of tumor-bearing rats at the volume of 0.02 mL/head. The therapeutic dose of each agent is defined in this study as follows: Miriplatin (400 μg/head, 20 mg/mL in LPD), cisplatin (400 μg/head, 20 mg/mL) and zinostatin stimalamer (20 μg/head, 1 mg/mL). After the intra-hepatic arterial administration, the gastroduodenal artery and abdomen are closed with uninterrupted sutures. The tumor growth rate (%) is calculated with the following formula: A7/A70 × 100, where A7 is the estimated tumor area at day 7 and A70 is the estimated tumor area at the initiation of the treatment (day 0). The systemic toxicity of the treatments is assessed in terms of changes in body weight during the experiments. These are calculated as (W7 − W70)/W70 × 100 where W7 is body weight at day 7 and W70 is body weight at day 0[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Kishimoto S, et al. Antitumor effects of a novel lipophilic platinum complex (SM-11355) against a slowly-growing rat hepatic tumor after intra-hepatic arterial administration. Biol Pharm Bull. 2000 Mar;23(3):344-8.

    [2]. Hanada M, et al. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol. 2009 Aug;64(3):473-83.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务